Payment overview · 2025
General Payments
$244.70
17 reported records · 5 companies
Healthcare provider profile · identity verified
Erica D Dearman, DO
Allopathic & Osteopathic Physicians|Family Medicine · PURCELL, OK · NPI 1497989248
Verified facts
What the public records show
CMS Open Payments records show Erica D Dearman, DO received $244.70 in general payments during 2025 across 17 reported records.
PFIZER INC. accounted for 55.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $135.78 | 55.5% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $43.44 | 17.8% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $43.18 | 17.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.69 | 6.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $6.61 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $244.70 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $109.58 | 7 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $109.58 | 7 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $109.58 | 7 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $43.44 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $43.18 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $26.20 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $26.20 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $6.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
66 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 413 | 114 |
| Atorvastatin Calcium | Atorvastatin Calcium | 263 | 90 |
| Sertraline Hcl | Sertraline Hcl | 246 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 196 | 71 |
| Losartan Potassium | Losartan Potassium | 178 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 178 | 53 |
| Lisinopril | Lisinopril | 177 | 54 |
| Gabapentin | Gabapentin | 154 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 142 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 142 | 47 |
| Omeprazole | Omeprazole | 132 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 127 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 113 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 43 |
| Ozempic | Semaglutide | 110 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 108 | 28 |
| Trazodone Hcl | Trazodone Hcl | 101 | 32 |
| Cephalexin | Cephalexin | 94 | 60 |
| Metformin Hcl | Metformin Hcl | 90 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 38 |
| Buspirone Hcl | Buspirone Hcl | 85 | 22 |
| Montelukast Sodium | Montelukast Sodium | 78 | 28 |
| Celecoxib | Celecoxib | 76 | 26 |
| Alendronate Sodium | Alendronate Sodium | 74 | 23 |
| Memantine Hcl | Memantine Hcl | 71 | 14 |
| Simvastatin | Simvastatin | 70 | 25 |
| Eliquis | Apixaban | 66 | 24 |
| Alprazolam | Alprazolam | 65 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 21 |
| Potassium Chloride | Potassium Chloride | 60 | 19 |
| Furosemide | Furosemide | 58 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 16 |
| Metformin Hcl Er | Metformin Hcl | 56 | 22 |
| Famotidine | Famotidine | 53 | 20 |
| Allopurinol | Allopurinol | 52 | 20 |
| Bupropion Xl | Bupropion Hcl | 48 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 46 | 17 |
| Tramadol Hcl | Tramadol Hcl | 45 | 15 |
| Donepezil Hcl | Donepezil Hcl | 44 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 14 |
| Prednisone | Prednisone | 42 | 32 |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | 11 |
| Meloxicam | Meloxicam | 38 | 12 |
| Pregabalin | Pregabalin | 37 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 20 |
| Carvedilol | Carvedilol | 34 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | 13 |
| Doxepin Hcl | Doxepin Hcl | 33 | suppressed |
| Jardiance | Empagliflozin | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | 11 |
| Nystatin | Nystatin | 30 | 16 |
| Estradiol | Estradiol | 29 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | 11 |
| Atenolol | Atenolol | 28 | 11 |
| Glimepiride | Glimepiride | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Naproxen | Naproxen | 22 | 11 |
| Valacyclovir | Valacyclovir Hcl | 22 | 12 |
| Clonidine Hcl | Clonidine Hcl | 21 | 11 |
| Bupropion Hcl | Bupropion Hcl | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 14 |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 16 |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 15 |
| Clonazepam | Clonazepam | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Temazepam | Temazepam | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Progesterone | Progesterone, Micronized | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $244.70 · 17 records | PFIZER INC. | ABRYSVO, AREXVY, COMIRNATY, ELIQUIS, FREESTYLE LIBRE 3, NURTEC ODT, OTEZLA, PREVNAR 20, REPATHA, SHINGRIX, VOQUEZNA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error